Usefulness of CTC and DTC-BM Detection for Adjuvant Therapy Effects and Prognosis Prediction in Early Breast Carcinoma: Results of 8–11 Years of Follow-up Evaluation

Autor: Kimio Uchida, Satoki Kinoshita, Hiroshi Takeyama, Takaki Shimada
Rok vydání: 2016
Předmět:
Adult
0301 basic medicine
Oncology
medicine.medical_specialty
medicine.medical_treatment
Bone Neoplasms
Breast Neoplasms
Cell Count
Gonadotropin-Releasing Hormone
03 medical and health sciences
0302 clinical medicine
Circulating tumor cell
Bone Marrow
Surgical oncology
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Adjuvant therapy
Humans
Cyclophosphamide
Aged
Epirubicin
Neoplasm Staging
Chemotherapy
Aromatase Inhibitors
business.industry
Carcinoma
Liver Neoplasms
Middle Aged
Neoplastic Cells
Circulating
Prognosis
Follow up evaluation
Tamoxifen
Treatment Outcome
030104 developmental biology
medicine.anatomical_structure
Chemotherapy
Adjuvant
030220 oncology & carcinogenesis
Female
Surgery
Fluorouracil
Bone marrow
business
Breast carcinoma
Adjuvant
Follow-Up Studies
Zdroj: Annals of Surgical Oncology. 24:1227-1233
ISSN: 1534-4681
1068-9265
DOI: 10.1245/s10434-016-5714-1
Popis: Circulating tumor cells (CTCs) reportedly have been detected in the peripheral blood of more than 50% of breast carcinoma cases with distant metastases. Moreover, the survival period is shorter for patients who had more than five CTCs after a single chemotherapy treatment. However, a few data show the relationships between CTCs and expressions of disseminated tumor cells in the bone marrow (DTCs-BM), including treatment effects and prognoses in early breast carcinomas.In this study, CTCs and DTC-BMs were measured by the CellSearch System for 20 patients with stages 1-3 carcinomas, who were followed for 8-11 years.CTCs in 2 (10%) of 20 breast carcinomas, more than 1 CTC was detected before adjuvant therapy, and both cases showed a decrease to 0 after chemotherapy. DTC-BMs in 19 (95%) of the 20 primary cases, more than 1 cell was found in the BM. After adjuvant therapy, 16 cases showed a decrease to 0-10 cells, 2 cases to 11-20 cells, and 2 cases to more than 21 cells. Six patients experienced recurrence. One of the two CTC-positive cases (21 cells) had bone and liver metastasis within 11 months. Among the DTC-BM cases, only 1 (16.7%) of the 6 primary patients with 11-20 cells had recurrence, whereas 4 (80%) of the 5 patients with more than 21 cells had recurrence 3-6 years later.Detection of DTC-BMs is useful for observing adjuvant therapy effects and for predicting relatively late-phase metastasis. The cluster status of CTCs suggests early relapsing.
Databáze: OpenAIRE
Externí odkaz: